Is an EAA > 0.6 in severe COVID-19 patients synonymous with a toxic and pro-inflammatory endotoxin profile, and should we treat it?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2197-425X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Is an EAA > 0.6 in severe COVID-19 patients synonymous with a toxic and pro-inflammatory endotoxin profile, and should we treat it? ; volume:9 ; number:1 ; day:12 ; month:3 ; year:2021 ; pages:1-3 ; date:12.2021
Intensive Care Medicine Experimental ; 9, Heft 1 (12.3.2021), 1-3, 12.2021
- Creator
-
Honore, Patrick M.
Redant, Sebastien
Bels, David De
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40635-021-00376-w
- URN
-
urn:nbn:de:101:1-2021050808330674364935
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Honore, Patrick M.
- Redant, Sebastien
- Bels, David De
- SpringerLink (Online service)
Other Objects (12)
Oxidative stress markers and septic acute kidney injury: Novel research avenue or road to nowhere?
Passive leg raising test with minimally invasive monitoring: the way forward for guiding septic shock resuscitation?
Adverse outcomes with extracorporeal adsorbent blood treatments in toxic systemic inflammation: a perspective on possible mechanisms
Eliminating endotoxin by polymyxin B hemoperfusion and/or continuous renal replacement therapy: should the focus be on timing, dosing, and type of renal epuration?
Efficacy of polymyxin B hemoperfusion in and beyond septic shock: is an “endotoxin severity score” needed?
Endotoxin removal by polymyxin B: is it a question of dose or duration or both?
Potential confounders in linking elevated S100A8/A9 to left ventricular dysfunction in septic shock patients
Beneficial effects of antioxidant therapy in crush syndrome in a rodent model: enough evidences to be used in humans?
Renal protection in sepsis: Is hypertonic sodium (lactate) the solution?
CytoSorb removes MDMA in vitro, but is it an effective therapy in vivo?
VCO2 calorimetry: stop tossing stones, it’s time for building!
Normal saline as resuscitation fluid in critically ill patients: not dead yet!
Oxidative stress markers and septic acute kidney injury: Novel research avenue or road to nowhere?
Passive leg raising test with minimally invasive monitoring: the way forward for guiding septic shock resuscitation?
Adverse outcomes with extracorporeal adsorbent blood treatments in toxic systemic inflammation: a perspective on possible mechanisms
Eliminating endotoxin by polymyxin B hemoperfusion and/or continuous renal replacement therapy: should the focus be on timing, dosing, and type of renal epuration?
Efficacy of polymyxin B hemoperfusion in and beyond septic shock: is an “endotoxin severity score” needed?
Endotoxin removal by polymyxin B: is it a question of dose or duration or both?
Potential confounders in linking elevated S100A8/A9 to left ventricular dysfunction in septic shock patients
Beneficial effects of antioxidant therapy in crush syndrome in a rodent model: enough evidences to be used in humans?
Renal protection in sepsis: Is hypertonic sodium (lactate) the solution?
CytoSorb removes MDMA in vitro, but is it an effective therapy in vivo?
VCO2 calorimetry: stop tossing stones, it’s time for building!
Normal saline as resuscitation fluid in critically ill patients: not dead yet!
Oxidative stress markers and septic acute kidney injury: Novel research avenue or road to nowhere?
Passive leg raising test with minimally invasive monitoring: the way forward for guiding septic shock resuscitation?
Adverse outcomes with extracorporeal adsorbent blood treatments in toxic systemic inflammation: a perspective on possible mechanisms
Eliminating endotoxin by polymyxin B hemoperfusion and/or continuous renal replacement therapy: should the focus be on timing, dosing, and type of renal epuration?
Efficacy of polymyxin B hemoperfusion in and beyond septic shock: is an “endotoxin severity score” needed?
Endotoxin removal by polymyxin B: is it a question of dose or duration or both?
Potential confounders in linking elevated S100A8/A9 to left ventricular dysfunction in septic shock patients
Beneficial effects of antioxidant therapy in crush syndrome in a rodent model: enough evidences to be used in humans?
Renal protection in sepsis: Is hypertonic sodium (lactate) the solution?
CytoSorb removes MDMA in vitro, but is it an effective therapy in vivo?
VCO2 calorimetry: stop tossing stones, it’s time for building!